Trial Profile
Didanosine/hydroxycarbamide in patients with HIV-1 infections
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs Didanosine/hydroxycarbamide (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Virostatics
- 02 Mar 2011 Substudy results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
- 20 Jul 2010 Status changed from recruiting to completed.
- 19 Jul 2010 Results presented at the the 18th International AIDS Conference (IAC-2010) in July 2010, according to a ViroStatics media release.